Latest Breaking News On - Suthesh sivapalaratnam - Page 1 : comparemela.com

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nordrhein westfalenUnited kingdomGlanzmann thrombastheniaSuthesh sivapalaratnamJoe vogelNature cardiovascular researchEuropean association for haemophiliaDrug administrationBarts healthQueen mary university of londonAnnual congressEuropean associationAllied disordersSenior directorProgram leadKingdom based phase

Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia

Bispecific antibodyHMB-001 positioned as the first prophylactic treatment for rare bleeding disorders CEO Benny Sorensen, MD, PhD, delivered the u.

United statesUnited kingdomCity ofSan franciscoViia fviiaGlanzmann thrombastheniaSuthesh sivapalaratnamBenny sorensenBarts healthNovo holdingsHealthcare conferenceUnited kingdom basedRichmond pharmacologyAdult haemostasisRoyal london hospitalBernard soulier syndrome